Table 7.
Current guideline recommendations for corticosteroids in severe asthma exacerbations
| Guideline (reference) | GINA [47] | ATS [54] | BTS [53] | Swiss [52] | NAEPP [55] | Japan [56] | TSANZ [57] |
|---|---|---|---|---|---|---|---|
| Drug | Prednisone | Prednisone | Prednisone | Prednisone | Prednisone | prednisone | Prednisone |
| Dose in mg | 40 | 37.5–50 | 40–50 | 40–50 | 40 | 0.5 mg/kgb | 40 |
| Duration | Up to 7 days° | 7 days | Until recovery (minimum 5 days) | 5–7 days | Up to 7 daysa | Usually less than 7 days | 5–10 days |
| Year | 2022 | 2019 | 2019 | 2018 | 2020 | 2020 | 2021 |
aIn patients failing to respond to inhaler therapy escalation over 3 days, for those who rapidly deteriorate, or for people with a history of brittle exacerbations. Severe exacerbation is objectively characterized by respiratory rate > 30/min, heart rate > 120/min, PEF < 50% pred or best, SpO2 < 90%, or use of accessory respiratory muscles. A life-threatening event additionally shows drowsiness, mental confusion, or a silent chest
bIn an emergency intravenous drip infusion of 200–500 mg of cortisol or 40–80 mg of methylprednisolone every 4–6 h as needed is possible until passage to oral formulations